<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Malin Ostensson | Ruth Palmer Lab</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/author/malin-ostensson/</link><atom:link href="https://deploy-preview-3--ruthpalmerlab.netlify.app/author/malin-ostensson/index.xml" rel="self" type="application/rss+xml"/><description>Malin Ostensson</description><generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Tue, 22 Sep 2020 00:00:00 +0000</lastBuildDate><image><url>https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.png</url><title>Malin Ostensson</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/author/malin-ostensson/</link></image><item><title>11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/</link><pubDate>Tue, 22 Sep 2020 00:00:00 +0000</pubDate><guid>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/dlg2_neuroblastoma/</guid><description/></item><item><title>Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGalpha) in neuroblastoma patient samples with chromosome arm 2p rearrangements</title><link>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/</link><pubDate>Wed, 01 Jan 2020 00:00:00 +0000</pubDate><guid>https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_patient_samples/</guid><description/></item></channel></rss>